C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology DaysGlobeNewsWire • 04/19/23
Down -29.73% in 4 Weeks, Here's Why You Should You Buy the Dip in C4 Therapeutics, Inc. (CCCC)Zacks Investment Research • 04/11/23
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/23/23
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 02/23/23
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid TumorsGlobeNewsWire • 01/30/23
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation MedicinesGlobeNewsWire • 01/09/23
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/03/23
Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 227%: Read This Before Placing a BetZacks Investment Research • 11/08/22
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/03/22
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/03/22
C4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 11/02/22
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid CancersGlobeNewsWire • 09/29/22
C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022GlobeNewsWire • 09/26/22
C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/04/22
C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D.GlobeNewsWire • 08/02/22
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null TumorsGlobeNewsWire • 05/16/22
C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/05/22
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of C4 Therapeutics, Inc. - CCCCNewsfile Corp • 04/21/22
C4 Therapeutics Stock Falls On CFT7455 Dose Limiting Toxicity In Multiple Myeloma TrialBenzinga • 04/08/22
C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 DegraderGlobeNewsWire • 04/08/22
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue SarcomaGlobeNewsWire • 03/09/22